Home

Johnson & Johnson (JNJ)

190.90
+0.18 (0.09%)
NYSE · Last Trade: Oct 14th, 2:25 AM EDT
QuoteNewsPress ReleasesChartHistoricalFAQAboutCompetitors
BMO Capital Lifts Protagonist Therapeutics Target On J&J Deal Hopes — Retail Traders Pile Instocktwits.com
Via Stocktwits · October 14, 2025
Big Money Move: Investment Manager Buys $6.9 Million Worth of Johnson & Johnson Shares, According to Recent Filingfool.com
Via The Motley Fool · October 13, 2025
Atai Life Sciences Remains Undervalued, Analyst Initiates With Around 125% Stock Upsidebenzinga.com
Atai Life Sciences' BPL-003 shows strong Phase 2b results for treatment-resistant depression, with potential $2.5 billion sales by 2035.
Via Benzinga · October 13, 2025
Johnson & Johnson Q3 Preview: With Stock Near All-Time Highs, Here's What To Watchbenzinga.com
Johnson & Johnson stock trades near all-time highs with an upcoming Q3 earnings report acting as the next catalyst.
Via Benzinga · October 13, 2025
Dividend Powerhouses: Should You Grab These 3 Before Earnings Drop?
As the Q3 2025 earnings season hits full stride, a critical question looms for income-focused investors: are "dividend powerhouses" still a safe haven, and should they be considered before their upcoming earnings reports? With market volatility persisting and interest rate trajectories influencing investor sentiment, the allure of stable returns from
Via MarketMinute · October 13, 2025
Why Did Protagonist Therapeutics Stock Soar Today?stocktwits.com
Via Stocktwits · October 10, 2025
Dow Jones Soars on Trump's Tariff Remarks, Signaling Market Volatility Amidst Trade Policy Shifts
New York, NY – October 13, 2025 – The Dow Jones Industrial Average has experienced significant upward momentum in recent months, notably jumping by hundreds of points on multiple occasions in early 2025, following pivotal statements from President Donald Trump regarding his administration's tariff policies. These sudden rallies underscore the profound sensitivity
Via MarketMinute · October 13, 2025
FDA Adds New Warning For Johnson & Johnson's Cancer Cell Therapybenzinga.com
FDA updates Johnson & Johnson's Carvykti label to warn of rare immune-related enterocolitis while reaffirming the therapy's overall benefit.
Via Benzinga · October 13, 2025
A Peek at Johnson & Johnson's Future Earningsbenzinga.com
Via Benzinga · October 13, 2025
Drug Stocks Just Had Their Best Week in 2 Decades. Should You Invest?fool.com
Now may be the time to invest in drug companies, as they just slipped the tariff noose.
Via The Motley Fool · October 13, 2025
Retail Investors' Top Stocks With Earnings This Week: Fastenal, ASML, TSMC And Morebenzinga.com
Retail investors are preparing for the kick-off of the Q3 earnings season, with big banks and other top stocks reporting this week.
Via Benzinga · October 13, 2025
Wall Street Suffers Worst Day Since April as Trump Revives Trade War Fearschartmill.com
U.S. markets were rattled on Friday after President Trump reignited trade tensions with China, triggering the sharpest sell-off since April. Tech and AI stocks led the decline, while gold and Treasuries saw renewed safe-haven demand.
Via Chartmill · October 13, 2025
Douglas Lane Adds $6 Million in J&J Stock Ahead of Earnings and Possible Biotech Dealfool.com
Via The Motley Fool · October 12, 2025
US Government Shutdown Rattles Global Markets, Igniting Uncertainty and Fueling Losses on October 10, 2025
The ongoing U.S. federal government shutdown, now in its tenth day as of October 10, 2025, has sent significant tremors through global financial markets. The persistent congressional deadlock over appropriations legislation for the 2026 fiscal year has intensified economic uncertainty worldwide, contributing to notable market losses across major indices.
Via MarketMinute · October 10, 2025
Market Turmoil: S&P 500 and Nasdaq Plunge Amidst Renewed Trade Tensions and AI Scrutiny
New York, NY – October 10, 2025 – U.S. equity markets experienced a dramatic downturn today, with both the S&P 500 and Nasdaq Composite indices recording substantial losses, shattering a months-long period of relative calm on Wall Street. The decline was fueled by a confluence of potent factors: renewed U.
Via MarketMinute · October 10, 2025
Johnson & Johnson In Talks To Acquire Protagonist Therapeutics: Reportbenzinga.com
Johnson & Johnson is in talks to buy Protagonist Therapeutics in a deal that could expand its immunology and cancer drug portfolio.
Via Benzinga · October 10, 2025
Is This Beaten-Down Dividend King a Buy?fool.com
This company's short life on the stock market has been a constant challenge.
Via The Motley Fool · October 10, 2025
Johnson & Johnson Gears Up For Q3 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analystsbenzinga.com
Via Benzinga · October 10, 2025
Pfizer (NYSE:PFE) Marks 348th Consecutive Dividend Payment: A Pillar of Stability Amidst Transformation
New York, NY – October 9, 2025 – Pfizer Inc. (NYSE:PFE) has once again affirmed its steadfast commitment to shareholder returns, declaring a $0.43 per-share cash dividend for the fourth quarter of 2025. This latest payout marks a significant milestone: the company's 348th consecutive quarterly dividend. The unwavering consistency of
Via MarketMinute · October 9, 2025
Government Shutdown Casts a Shadow: Economic Data Halted, Federal Reserve Navigates Blind
The ongoing government shutdown has plunged financial markets into a state of heightened uncertainty, as the vital flow of economic data—the lifeblood of informed decision-making—grinds to a halt. With key agencies like the Bureau of Labor Statistics (BLS), Bureau of Economic Analysis (BEA), and the Census Bureau ceasing
Via MarketMinute · October 9, 2025
Pfizer's 348th Consecutive Dividend: A Beacon of Stability Amidst Industry Headwinds
New York, NY – October 9, 2025 – Pfizer Inc. (NYSE: PFE) has once again affirmed its steadfast commitment to shareholder returns, declaring a $0.43 per-share cash dividend for the fourth quarter of 2025. This payment marks a significant milestone as the company's 348th consecutive quarterly dividend, a testament to its
Via MarketMinute · October 9, 2025
Dow Jones Takes a Tumble Amidst Government Shutdown Fears and Economic Headwinds
The Dow Jones Industrial Average (DJIA) experienced a notable slide today, October 9, 2025, as a confluence of a U.S. government shutdown, mounting economic concerns, and specific corporate disappointments sent ripples of apprehension through the financial markets. This downturn signals a renewed period of volatility, challenging investor confidence and
Via MarketMinute · October 9, 2025
What Analysts Are Saying About Johnson & Johnson Stockbenzinga.com
Via Benzinga · October 9, 2025
Top US Bankers Sound Alarm: Brace for Potential Stock Market Decline
In a series of recent and increasingly pointed warnings, some of America's most influential financial leaders are cautioning investors to prepare for a significant stock market downturn within the coming years. This chorus of cautionary outlooks, spearheaded by figures such as Jamie Dimon of JPMorgan Chase, Larry Fink of BlackRock,
Via MarketMinute · October 9, 2025
Investors Brace for Pullback as Short-Bias ETF Inflows Signal Growing Bearishness
A significant surge in capital flowing into short-bias Exchange-Traded Funds (ETFs) has sent a clear signal through the financial markets: investor sentiment is shifting towards caution and a potential stock market pullback. This notable trend, particularly pronounced in recent weeks, suggests that a growing number of investors are actively positioning
Via MarketMinute · October 9, 2025